Sunshine Biopharma (SBFM) Return on Capital Employed (2016 - 2026)
Sunshine Biopharma's (SBFM) quarterly Return on Capital Employed came in at 27.36% in Q1 2026, down 368.0% YoY from 10.21% in Q1 2025, and down 6.93% on a QoQ basis from 25.58% in Q4 2025.
Sunshine Biopharma (SBFM) Return on Capital Employed (2016 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has 11 years of Return on Capital Employed data on file, last reported at 27.36% in Q1 2026.
- Quarterly Return on Capital Employed fell 368.0% year-over-year to 27.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27.36% (down 368.0% YoY) and the FY2025 annual result came in at 26.08%, down 41.0% from the prior year.
- Return on Capital Employed eased to 27.36% in Q1 2026, from 25.58% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 9.57% in Q3 2022 to a low of 130.15% in Q1 2023.
- A 5-year average of 43.88% and a median of 25.58% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 27810 bps — and 2023, when it plunged 11143 bps.
- Tracing SBFM's Return on Capital Employed over 5 years: stood at 96.01% in 2022, then surged by 77 bps to 21.91% in 2023, then retreated by 10 bps to 24.02% in 2024, then slipped by 7 bps to 25.58% in 2025, then dropped by 7 bps to 27.36% in 2026.
- The last three Return on Capital Employed figures came in at 27.36% (Q1 2026), 25.58% (Q4 2025), and 25.82% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Sunshine Biopharma | 1.58 Mn | -12.17 Mn | 2.43 Mn | -23.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.39% |
| Mar 31, 2026 | -27.36% |
| Dec 31, 2025 | -25.58% |
| Sep 30, 2025 | -25.82% |
| Jun 30, 2025 | -25.98% |
| Mar 31, 2025 | -23.67% |
| Dec 31, 2024 | -24.02% |
| Sep 30, 2024 | -19.53% |
| Jun 30, 2024 | -18.12% |
| Mar 31, 2024 | -18.76% |
| Dec 31, 2023 | -21.91% |
| Sep 30, 2023 | -117.63% |
| Jun 30, 2023 | -121.20% |
| Mar 31, 2023 | -130.15% |
| Dec 31, 2022 | -96.01% |
| Sep 30, 2022 | -9.57% |
| Jun 30, 2022 | -9.77% |
| Mar 31, 2022 | -30.97% |
| Dec 31, 2021 | -107.91% |
| Sep 30, 2021 | -148.34% |